Share

A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel syndrome

Start/End Date

2017 – ongoing

Principal Investigator

Prof. Michele Guarino

Host Institution

Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven (centro coordinatore internazionale)

Other Institution involved

Unità Operativa di Gastroenterologia, Università campus Biomedico di Roma
25 centers in 4 countries involved (Spain, Belgium, Germany, Italy)

Funding source

Azienda farmaceutica Cosmo Technologies Ltd (sponso)

magnifiercrossmenuchevron-downchevron-leftchevron-right